ALDA Pharmaceuticals Corp.
TSX VENTURE : APH

ALDA Pharmaceuticals Corp.

January 04, 2007 13:01 ET

T36'R' Disinfectant Receives CDC Certificate of Approval in China

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Jan. 4, 2007) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") has received its certificate of approval from the Fujian Centre of Disease Control for T36® Disinfectant after passing all of the required tests as reported by the company in a news release dated November 30, 2006. This certificate has allowed ALDA's agent to apply to the Chinese National Centre for Health Inspection and Supervision for approval to manufacture T36® Disinfectant for sale in China and for export. ALDA has been advised that a response may be obtained within 90 days. Dr. Terrance Owen, President & CEO states, "This approval, coupled with our developing patent protection, is a very important step in securing international sales of T36® Disinfectant, particularly in Asia. We look forward to receiving manufacturing approval in China which will be the culmination of over two years of effort on our part and by our agent, who has been relentless in the pursuit of this goal. Our goal is to achieve lower manufacturing costs leading to increased sales and greater profitability."

About ALDA

ALDA has developed and markets wide spectrum, non-toxic, non-corrosive, biodegradable infection control products based on its patent-pending T36® technology. Its lead product, T36® Disinfectant, is acknowledged to be effective against all fungi, bacteria, viruses including Avian Flu, SARS, Norwalk Virus, HIV, Legionella and Hepatitis because of its ability to kill polio and TB.

Terrance G. Owen, Ph.D., MBA, President, CEO and Director

ALDA Pharmaceuticals Corp.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information